Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Gene therapies save search
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
TSHA | $2.575 4.68% 240K
|
Health Technology
|
| O: 3.62%
H: 8.2%
C: 6.85%
tsha-120 gene therapies report positive gene therapy
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101
Published: 2022-01-27 (Crawled : 12:30) - biospace.com/
TSHA | $2.575 4.68% 240K
|
Health Technology
|
| O: 2.88%
H: 1.27%
C: -13.34%
tsha-101 gene therapies positive gene therapy therapy biomarkers tsha-102
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
Published: 2021-12-22 (Crawled : 12:30) - biospace.com/
TSHA | $2.575 4.68% 240K
|
Health Technology
|
| O: -0.59%
H: 1.04%
C: -2.01%
disease gene therapies positive gene therapy designation
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
RCKT M | $24.39 2.18% 25K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
treatment ema als anemia gene therapies positive gene therapy
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
Published: 2021-12-06 (Crawled : 23:00) - biospace.com/
TSHA | $2.575 4.68% 240K
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: 0.0%
treatment presentation preclinical gene therapies potential positive gene therapy pre-clinical
Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
TSHA | $2.575 4.68% 240K
|
Health Technology
|
| O: -3.46%
H: 4.94%
C: 1.27%
media gene therapies positive preclinical gene therapy therapy pre-clinical
Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis
Published: 2021-10-21 (Crawled : 11:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 9.3%
H: 12.98%
C: 0.43%
ongoing gene therapies phase 1 gene therapy positive therapy biomarkers
Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development
Published: 2021-09-15 (Crawled : 12:00) - biospace.com/
TSHA | $2.575 4.68% 240K
|
Health Technology
|
| O: 0.15%
H: 5.48%
C: 4.5%
gene therapies potential positive therapy molecular gene therapy preclinical syndros pre-clinical tsha-102
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults
Published: 2021-07-19 (Crawled : 17:00) - biospace.com/
BMRN | $91.55 2.3% 130K
|
Health Technology
|
| O: -1.84%
H: 2.39%
C: 1.79%
presentation gene therapy positive therapy results phase 3 trial gene therapies
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
Published: 2021-07-19 (Crawled : 15:00) - prnewswire.com
BMRN | $91.55 2.3% 130K
|
Health Technology
|
| O: -1.84%
H: 2.39%
C: 1.79%
presentation gene therapy positive therapy results phase 3 trial gene therapies
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
Published: 2021-07-09 (Crawled : 13:00) - biospace.com/
BLUE | $0.9601 0.68% 330K
|
Health Technology
|
| O: 0.0%
H: 2.73%
C: 0.46%
gene therapy positive therapy gene therapies
Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Disease Pathology
Published: 2021-07-07 (Crawled : 12:00) - biospace.com/
SEEL | $0.3257 11K
|
Health Technology
|
| O: 2.42%
H: 1.69%
C: -10.47%
crispr disease gene therapy positive therapy parkinson gene therapies
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
Published: 2021-06-22 (Crawled : 16:00) - globenewswire.com
QURE | $4.84 0.42% 34K
|
Health Technology
|
| O: 7.4%
H: 0.77%
C: -13.44%
gene therapy positive therapy trial gene therapies
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
Published: 2021-05-21 (Crawled : 13:00) - biospace.com/
BLUE | $0.9601 0.68% 330K
|
Health Technology
|
| O: 0.98%
H: 2.74%
C: 1.71%
gene therapy positive therapy gene therapies chmp
Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting
Published: 2021-05-14 (Crawled : 13:00) - globenewswire.com
RARE F | $44.02 0.76% 49K
|
Health Technology
|
| O: 1.39%
H: 3.38%
C: 2.49%
ongoing phase 1 gene therapy positive therapy multi-year phase 3 phase 2 gene therapies
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
Published: 2021-03-15 (Crawled : 12:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 0.71%
H: 3.52%
C: -2.46%
gene therapies positive therapy gene therapy milestone
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
Published: 2021-02-12 (Crawled : 17:00) - globenewswire.com
ABEO | News | $4.075 -44.63% 990K
|
Health Technology
|
| O: -1.13%
H: 12.88%
C: -10.9%
treatment phase 1 gene therapy positive therapy phase 3 phase 2 gene therapies aβos
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
Published: 2021-02-08 (Crawled : 20:00) - globenewswire.com
FOLD F | $10.85 0.28% 31K
|
Health Technology
|
| O: 0.76%
H: 0.7%
C: -3.95%
gene therapy positive therapy disease gene therapies preclinical pre-clinical
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
Published: 2021-02-08 (Crawled : 20:00) - globenewswire.com
FOLD F | $10.85 0.28% 31K
|
Health Technology
|
| O: 0.76%
H: 0.7%
C: -3.95%
gene therapy positive therapy disease gene therapies
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
Published: 2021-01-10 (Crawled : 00:11) - prnewswire.com
BMRN | $91.55 2.3% 130K
|
Health Technology
|
| O: -6.61%
H: 1.28%
C: -3.19%
gene therapy positive therapy results phase 3 trial trial results gene therapies
Gainers vs Losers
| 84% | 16% |
Top 10 Gainers
MTTR | News M | $4.625 165.81% 5.5M
|
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
PALI | $7.64 54.97% 14M
|
Manufacturing
OPRT | News | $3.19 41.78% 3M
|
Finance
PEGY | $0.0629 37.34% 110M
|
Manufacturing
MLEC | $1.87 33.57% 1.6M
|
n/a
ATGL | $3.66 27.97% 150K
|
VNRX | $0.759 26.5% 390K
|
Health Technology
SMFL | $5.35 22.99% 11M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.